NEW YORK (TheStreet) -- CHANGE IN RATINGS
Apple rated new buy at Cantor. $777 price target. Stock has been challenged this year, but appears to be in the midst of a recovery.
Asbury Automotive upgraded at Keybanc from hold to buy. $60 price target. Estimates also boosted, given higher industry demand.
Allison Transmission upgraded at Goldman to buy. $27 price target. End-market demand is improving and the company gives back its free cash flow in dividends.
Best Buy upgraded at BofA/Merrill from underperform to neutral. $38 price target. Company is cutting costs faster than expected.
Beam downgraded at Argus from buy to hold, Argus said. Stock is trading at a premium to its peers.
Centerra Gold downgraded at UBS to neutral from buy and given a $5.69 price target, said UBS. Higher political risk will make the recent run in the stock difficult to continue.
CNA Financial rated new buy at Deutsche. $42 price target. Company trades at a deep discount to its peers, but management can expand margins.
Concur Technologies downgraded at Wunderlich from buy to hold. $96 price target. 2014 consensus earnings expectations appear too high.
Gulfport Energy rated new Outperform at Wells. Company's core asset appears to be in a sweet spot of the Utica shale.
Guidewire Software downgraded at Citi to sell from neutral and given a $37 price target, said Citigroup. Revenue growth is decelerating and expenses are ramping, making valuation difficult.
Invensense upgraded at Baird from neutral to outperform, Robert Baird said. $23 price target. Design win momentum has swung back to the company's favor.
Loews rated new Buy at Deutsche. $52 price target. Company is the cheapest of its peers, but can compound book value.
Microsoft was downgraded at Morgan Stanley to equal-weight, Morgan Stanley said. Nokia deal adds risk to the company's model.
Nokia upgraded at BMO from underperform to market perform, BMO Capital said. $5 price target. MSFT deal terms are very positive for the company.
ServiceNow rated new outperform at JMP Securities. $56 price target. Company is a cloud leader in IT Service Management.
Pharmacyclics upgraded at Lazard to buy, Lazard Capital Markets said. $141 price target. Checks show a strong outlook for ibrutinib.
Rowan upgraded at JP Morgan from neutral to overweight, JP Morgan said. Dayrates have likely bottomed. $39 price target.
Select Medical downgraded at Wells from market perform to underperform, Wells Fargo said. Long-term acute care hospitals will face Medicare reimbursement risks in 2015.
Vivus downgraded at Lazard to sell, Lazard Capital Markets said. $8 price target. Qsymia has had a slow launch and the company's patents could face competition.
Verizon upgraded at Baird from neutral to outperform, Robert Baird said. $53 price target. VZW purchase should benefit long-term positioning and earnings growth.
STOCK COMMENTS / EPS CHANGES Abbott Laboratories
numbers lowered at Jefferies. Shares of ABT now seen reaching $44, Jefferies said. Estimates also lowered on model adjustment. Buy rating.
eBay added to Best Ideas List at Wedbush. EBAY was placed on the Best Ideas list, according to Wedbush. Paypal is winning and marketplace growth is reaccelerating. Outperform rating and $64 price target.
Halliburton estimates, target raised at Sterne Agee. Shares of HAL now seen reaching $63, according to Sterne Agee. Estimates also increased, following the company's dutch auction repurchase. Buy rating.
Microsoft estimates, target reduced at BMO. Shares of MSFT now seen reaching $35, according to BMO Capital. Estimates also cut, as the Nokia deal will cut into earnings.
>To submit a news tip, email: firstname.lastname@example.org.
Follow TheStreet on Twitter and become a fan on Facebook.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.
- Investment & Company Information